EUR J CANCER - European Journal of Cancer

Academic

Journals

Publications: 18,148| Citation Count: 110,314 (Self-Citation: 4161)|H-Index: 91
Year Range: 1992-2011

Interests: Oncology

Homepage

Cumulative Annual

Order by:

Publications (18148)

Breast cancer screening (Citations: 6)

Philippe Autier

Journal: European Journal of Cancer - EUR J CANCER , vol. 47, pp. S133-S146, 2011
Screening for prostate cancer (Citations: 6)

Fritz H. Schröder, Donna P. Ankerst, Ian M. Thompson

Journal: European Journal of Cancer - EUR J CANCER , vol. 47, pp. S164-S170, 2011
The relationship between new-onset diabetes mellitus and pancreatic cancer risk: A case–control study (Citations: 2)

Qiwen Ben, Quancai Cai, Zhaoshen Li, Yaozong Yuan, Xiaoyan Ning, Shangxin Deng, Kaixuan Wang

Journal: European Journal of Cancer - EUR J CANCER , vol. 47, no. 2, pp. 248-254, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) (Citations: 4)

Rabab M. Gaafar, Veerle F. Surmont, Giorgio V. Scagliotti, Rob J. Van Klaveren, Demetris Papamichael, John J. Welch, Baktiar Hasan, Valter Torri, Jan P. van Meerbeeck

Journal: European Journal of Cancer - EUR J CANCER , vol. 47, no. 15, pp. 2331-2340, 2011
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study (Citations: 2)

C. Villanueva, A. Awada, M. Campone, J. P. Machiels, T. Besse, E. Magherini, F. Dubin, D. Semiond, X. Pivot

Journal: European Journal of Cancer - EUR J CANCER , vol. 47, no. 7, pp. 1037-1045, 2011

Authors (49443)

Keywords (4781)

Publications (18148)

Breast cancer screening (Citations: 6)

Screening for prostate cancer (Citations: 6)

The relationship between new-onset diabetes mellitus and pancreatic cancer risk: A case–control study (Citations: 2)

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) (Citations: 4)

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study (Citations: 2)